Thus, European guidelines recommend sRP should only be considered for patients with few comorbidities and LE of ≥10 yrs, pre-sRP PSA < 10 ng/ml with no lymph node involvement or evidence of metastatic disease, and at initial diagnosis, GS ≤ 8 and clinical stage T1 or T2 [16]. Here, KLK3 is linked to metastatic neoplasm.